Genetic Factors Modify the Risk of Developing Beryllium Disease

HLA-DPB1 HLA-DQB1

[1]  Jenny R. Roberts,et al.  Skin as a route of exposure and sensitization in chronic beryllium disease. , 2003, Environmental health perspectives.

[2]  D. Monos,et al.  Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. , 2002, American journal of respiratory and critical care medicine.

[3]  L. Newman,et al.  High Beryllium-stimulated TNF- α Is Associated with the − 308 TNF- α Promoter Polymorphism and with Clinical Severity in Chronic Beryllium Disease , 2001 .

[4]  B. Marrone,et al.  Beryllium sensitivity is linked to HLA-DP genotype. , 2001, Toxicology.

[5]  M. Amicosante,et al.  Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69. , 2001, Human immunology.

[6]  M. McCawley,et al.  Ultrafine beryllium number concentration as a possible metric for chronic beryllium disease risk. , 2001, Applied occupational and environmental hygiene.

[7]  M. Rossman.  Chronic beryllium disease: a hypersensitivity disorder. , 2001, Applied occupational and environmental hygiene.

[8]  M. Kolanz.  Introduction to beryllium: uses, regulatory history, and disease. , 2001, Applied occupational and environmental hygiene.

[9]  R. Allen.  Polymorphism of the human TNF-α promoter — random variation or functional diversity? , 1999 .

[10]  P. S. White,et al.  Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. , 1999, Journal of immunology.

[11]  M. Amicosante,et al.  Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. , 1998, The European respiratory journal.

[12]  L. Newman,et al.  Metals that cause sarcoidosis. , 1998, Seminars in Respiratory Infections.

[13]  L. Newman,et al.  Expansions of T-cell subsets expressing particular T-cell receptor variable regions in chronic beryllium disease. , 1998, American journal of respiratory cell and molecular biology.

[14]  L. Newman,et al.  Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease. , 1997, American journal of respiratory and critical care medicine.

[15]  J. Strominger,et al.  HLA-DP2: self peptide sequences and binding properties. , 1997, Journal of immunology.

[16]  L. Richeldi,et al.  Interaction of genetic and exposure factors in the prevalence of berylliosis. , 1997, American Journal of Industrial Medicine.

[17]  H. Wiedemann,et al.  Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. , 1997, Occupational and environmental medicine.

[18]  L S Newman,et al.  Beryllium induces IL-2 and IFN-gamma in berylliosis. , 1997, Journal of immunology.

[19]  L. Newman,et al.  Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. , 1996, The American journal of pathology.

[20]  L S Newman,et al.  The natural history of beryllium sensitization and chronic beryllium disease. , 1996, Environmental health perspectives.

[21]  P. Carré,et al.  Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and interleukin-6 but not interleukin-1 beta. , 1994, American journal of respiratory cell and molecular biology.

[22]  L. V. D. van de Putte,et al.  A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha , 1994, European journal of immunology.

[23]  L. Richeldi,et al.  HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. , 1993, Science.

[24]  K. Kreiss,et al.  Epidemiology of beryllium sensitization and disease in nuclear workers. , 1993, The American review of respiratory disease.

[25]  F. Pociot,et al.  An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles , 1993, The Journal of experimental medicine.

[26]  A. Blakemore,et al.  Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. , 1992, Human molecular genetics.

[27]  P. Haley.  Mechanisms of granulomatous lung disease from inhaled beryllium: the role of antigenicity in granuloma formation. , 1991, Toxicologic pathology.

[28]  H. Mcdevitt,et al.  Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Strieter,et al.  Cellular and molecular aspects of granulomatous inflammation. , 1989, American journal of respiratory cell and molecular biology.

[30]  R. Crystal,et al.  Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. , 1989, The New England journal of medicine.

[31]  N. Morling,et al.  Association between HLA‐DR2 and Production of Tumour Necrosis Factor α and Interleukin 1 by Mononuclear Cells Activated by Lipopolysaccharide , 1988, Scandinavian journal of immunology.

[32]  M. Eisenbud,et al.  Origins of the standards for control of beryllium disease (1947-1949). , 1982, Environmental research.

[33]  E. D. Cyan.  Handbook of Chemistry and Physics , 1970 .

[34]  I. Sneddon.  Beryllium Disease , 1958, Postgraduate medical journal.

[35]  S. Marsh.  Nomenclature for factors of the HLA system, update September 2000. WHO Nomenclature Committee for Factors of the HLA System. , 2000, Tissue antigens.

[36]  S. Marsh.  Nomenclature for factors of the HLA system, update October 1998. WHO Nomenclature Committee for Factors of the HLA System. , 1999, Tissue antigens.

[37]  L. Abraham,et al.  The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. , 1997, Molecular immunology.

[38]  K. Kreiss,et al.  Machining risk of beryllium disease and sensitization with median exposures below 2 micrograms/m3. , 1996, American journal of industrial medicine.

[39]  A. Lansdown,et al.  Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. , 1995, Critical reviews in toxicology.

[40]  A. Svejgaard,et al.  HLA and disease associations: detecting the strongest association. , 1994, Tissue antigens.

[41]  D. Kwiatkowski,et al.  Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. , 1994, Nature.

[42]  P. D. Thomas,et al.  Current concepts of the pathogenesis of sarcoidosis. , 1987, The American review of respiratory disease.

[43]  O. Alekseeva.  [Study of the ability of beryllium compounds to produce delayed type allergy]. , 1965, Gigiena truda i professional'nye zabolevaniia.

[44]  H. S. Vanordstrand.  Beryllium Poisoning. , 1946, British medical journal.